EP1503739A4 - Sustained release of guaifenesin combination drugs - Google Patents
Sustained release of guaifenesin combination drugsInfo
- Publication number
- EP1503739A4 EP1503739A4 EP03736462A EP03736462A EP1503739A4 EP 1503739 A4 EP1503739 A4 EP 1503739A4 EP 03736462 A EP03736462 A EP 03736462A EP 03736462 A EP03736462 A EP 03736462A EP 1503739 A4 EP1503739 A4 EP 1503739A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- sustained release
- combination drugs
- guaifenesin
- guaifenesin combination
- drugs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US121706 | 2002-04-15 | ||
US10/121,706 US6955821B2 (en) | 2000-04-28 | 2002-04-15 | Sustained release formulations of guaifenesin and additional drug ingredients |
US10/406,557 US7838032B2 (en) | 2000-04-28 | 2003-04-04 | Sustained release of guaifenesin |
US406557 | 2003-04-04 | ||
US10/406,574 US7985420B2 (en) | 2000-04-28 | 2003-04-04 | Sustained release of guaifenesin combination drugs |
US406574 | 2003-04-04 | ||
PCT/US2003/011500 WO2003088952A1 (en) | 2002-04-15 | 2003-04-15 | Sustained release of guaifenesin combination drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1503739A1 EP1503739A1 (en) | 2005-02-09 |
EP1503739A4 true EP1503739A4 (en) | 2006-06-21 |
Family
ID=29255202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03736462A Ceased EP1503739A4 (en) | 2002-04-15 | 2003-04-15 | Sustained release of guaifenesin combination drugs |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1503739A4 (en) |
JP (1) | JP5466346B2 (en) |
CN (1) | CN1655766B (en) |
AU (1) | AU2003237807B2 (en) |
CA (1) | CA2481739C (en) |
EA (1) | EA007156B1 (en) |
IL (1) | IL164438A0 (en) |
MX (1) | MXPA04010225A (en) |
WO (1) | WO2003088952A1 (en) |
ZA (1) | ZA200409171B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8578501A1 (en) | 2002-07-25 | 2005-02-04 | Pharmacia Corp | DOSAGE FORM ONCE A DAY OF PRAMIPEXOL |
KR20060076319A (en) * | 2003-09-24 | 2006-07-04 | 콤비네이토릭스, 인코포레이티드 | Therapeutic regimens for administering drug combinations |
CA2476101A1 (en) * | 2004-08-12 | 2006-02-12 | Bernard Charles Sherman | Extended-release capsules comprising venlafaxine hydrochloride |
EA201001083A1 (en) * | 2004-08-13 | 2011-08-30 | Бёрингер Ингельхайм Интернациональ Гмбх | COMPOSITION OF TABLET OF PROLONGED SURVIVING, CONTAINING PRAMIPEXOL OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, METHOD OF ITS MANUFACTURE AND ITS APPLICATION |
LT2474545T (en) | 2005-12-13 | 2017-02-27 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
CN1994285B (en) * | 2006-01-04 | 2011-03-16 | 上海医药工业研究院 | Sustained release micro-pellet of guaifenesin and preparation process thereof |
US20080176955A1 (en) * | 2007-01-16 | 2008-07-24 | Victory Pharma, Inc. | Combined administration of benzonatate and guaifenesin |
CN101658507B (en) * | 2008-08-26 | 2011-12-07 | 北京科信必成医药科技发展有限公司 | Glyceryl guaiacolate and pseudoephedrine compound sustained release preparation |
DK2394648T3 (en) | 2009-02-04 | 2016-09-26 | Astellas Pharma Inc | A pharmaceutical composition for oral administration |
KR20220015492A (en) | 2010-03-10 | 2022-02-08 | 인사이트 홀딩스 코포레이션 | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
US9339478B2 (en) | 2011-02-04 | 2016-05-17 | Reckitt Benckiser Llc | Pharmaceutical formulation |
EP2721028B1 (en) | 2011-06-20 | 2015-11-04 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
CN102755304A (en) * | 2012-08-03 | 2012-10-31 | 四川百利药业有限责任公司 | Preparation method of guaifenesin and dextromethorphan hydrobromide capsules |
PE20200175A1 (en) | 2012-11-15 | 2020-01-24 | Incyte Holdings Corp | SUSTAINED RELEASE RUXOLITINIB DOSAGE FORMS |
CA3155500A1 (en) | 2013-08-07 | 2015-02-12 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
CN105982860B (en) * | 2015-02-11 | 2020-04-14 | 北京科信必成医药科技发展有限公司 | Guaifenesin water-free swallowable taste-masking granule |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4552899A (en) * | 1984-04-09 | 1985-11-12 | Analgesic Associates | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
EP0384514A2 (en) * | 1989-02-21 | 1990-08-29 | Norwich Eaton Pharmaceuticals, Inc. | Dual-action tablet |
WO2000033818A1 (en) * | 1998-12-11 | 2000-06-15 | Nostrum Pharmaceuticals, Inc. | Sustained release tablet containing hydrocolloid and cellulose ether |
WO2001019901A2 (en) * | 1999-09-14 | 2001-03-22 | Smithkline Beecham Corporation | Process for making aqueous coated beadlets |
US20020022058A1 (en) * | 2000-07-08 | 2002-02-21 | Lovercheck Dale R. | Unit dose of material in system and method |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6372525B1 (en) * | 1999-12-20 | 2002-04-16 | Taiwan Semiconductor Manufacturing Company | Wafer-level antenna effect detection pattern for VLSI |
US6372252B1 (en) * | 2000-04-28 | 2002-04-16 | Adams Laboratories, Inc. | Guaifenesin sustained release formulation and tablets |
-
2003
- 2003-04-15 EA EA200401369A patent/EA007156B1/en not_active IP Right Cessation
- 2003-04-15 MX MXPA04010225A patent/MXPA04010225A/en active IP Right Grant
- 2003-04-15 WO PCT/US2003/011500 patent/WO2003088952A1/en active Application Filing
- 2003-04-15 JP JP2003585704A patent/JP5466346B2/en not_active Expired - Fee Related
- 2003-04-15 AU AU2003237807A patent/AU2003237807B2/en not_active Ceased
- 2003-04-15 CA CA2481739A patent/CA2481739C/en not_active Expired - Lifetime
- 2003-04-15 EP EP03736462A patent/EP1503739A4/en not_active Ceased
- 2003-04-15 IL IL16443803A patent/IL164438A0/en unknown
- 2003-04-15 CN CN038125110A patent/CN1655766B/en not_active Expired - Fee Related
-
2004
- 2004-11-11 ZA ZA2004/09171A patent/ZA200409171B/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4552899A (en) * | 1984-04-09 | 1985-11-12 | Analgesic Associates | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
US4552899B1 (en) * | 1984-04-09 | 1992-10-20 | Analgesic Associates | |
EP0384514A2 (en) * | 1989-02-21 | 1990-08-29 | Norwich Eaton Pharmaceuticals, Inc. | Dual-action tablet |
WO2000033818A1 (en) * | 1998-12-11 | 2000-06-15 | Nostrum Pharmaceuticals, Inc. | Sustained release tablet containing hydrocolloid and cellulose ether |
WO2001019901A2 (en) * | 1999-09-14 | 2001-03-22 | Smithkline Beecham Corporation | Process for making aqueous coated beadlets |
US20020022058A1 (en) * | 2000-07-08 | 2002-02-21 | Lovercheck Dale R. | Unit dose of material in system and method |
Non-Patent Citations (1)
Title |
---|
See also references of WO03088952A1 * |
Also Published As
Publication number | Publication date |
---|---|
EA200401369A1 (en) | 2005-06-30 |
IL164438A0 (en) | 2005-12-18 |
AU2003237807A1 (en) | 2003-11-03 |
ZA200409171B (en) | 2005-07-27 |
CA2481739A1 (en) | 2003-10-30 |
WO2003088952A1 (en) | 2003-10-30 |
JP5466346B2 (en) | 2014-04-09 |
CA2481739C (en) | 2012-10-02 |
EP1503739A1 (en) | 2005-02-09 |
MXPA04010225A (en) | 2005-07-05 |
JP2005528402A (en) | 2005-09-22 |
CN1655766B (en) | 2012-05-30 |
AU2003237807B2 (en) | 2008-10-23 |
EA007156B1 (en) | 2006-08-25 |
CN1655766A (en) | 2005-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL236190A0 (en) | Sustained release of antiinfectives | |
EP1537880A4 (en) | Sustained release preparation | |
EP1503739A4 (en) | Sustained release of guaifenesin combination drugs | |
EP1549296A4 (en) | Sustained release formulations of metformin | |
IL166424A0 (en) | Sustained release formulations comprising lamotigine | |
IL173866A0 (en) | Sustained release dosage forms of ziprasidone | |
EP1581236A3 (en) | Sustained release of antiinfectives | |
HK1107672A1 (en) | Conveniently implantable sustained release drug compositions | |
HK1084043A1 (en) | Derivatives of aryl-quinazoline/aryl-2amino-phenylmethanone which promote the release of parathyroidhormone | |
IL174958A0 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
AU2003260803A8 (en) | Sustained release pharmaceutical composition | |
IL176222A0 (en) | Sustained release torsemide dosage forms | |
TWI319318B (en) | Modified release pharmaceutical formulation | |
EP1564220A4 (en) | Sustained release drug carrier | |
EP1802346A4 (en) | Sustained release pharmaceutical composition | |
EP1411904A4 (en) | Sustained release pharmaceutical composition | |
PL376840A1 (en) | Prolonged release pharmaceutical composition | |
GB0202900D0 (en) | Novel formulations of drugs | |
EP1478353A4 (en) | Sustained release pharmaceutical composition | |
GB0119848D0 (en) | Delayed and sustained drug release | |
EP1483580A4 (en) | Biomarker for efficacy of appetite suppressant drugs | |
IL176061A0 (en) | Nitrooxyderivatives of antihypertensive drugs | |
EP1501844A4 (en) | Disaccharides for drug discovery | |
EP1652522A4 (en) | Sustained release tablet for oral use | |
GB0327742D0 (en) | Novel uses of known drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20041029 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1072906 Country of ref document: HK |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ADAMS RESPIRATORY THERAPEUTICS, INC. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060523 |
|
17Q | First examination report despatched |
Effective date: 20071031 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: RECKITT, BENCKISER, INC. |
|
APBK | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOSNREFNE |
|
APBN | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2E |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: RECKITT BENCKISER LLC |
|
APBR | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3E |
|
APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |
|
APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1072906 Country of ref document: HK |
|
APBT | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9E |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20150126 |